


What is claimed is:

1. A cyclic peptide of Formula (II):



wherein:

5 AA^{Sc} is an amino acid side chain;

R^{1a}, R^{1b}, and R^{1c} are each independently a 6- to 14-membered aryl or a 6- to 14-membered heteroaryl;

R^{2a}, R^{2b}, R^{2c} and R^{2d} are independently an amino acid side chain;

10 at least one of R^{2a}, R^{2b}, R^{2c} and R^{2d} is ,

, or a protonated form thereof;

at least one of R^{2a}, R^{2b}, R^{2c} and R^{2d} is guanidine or a protonated form thereof;


each n'' is independently an integer from 0 to 5;

each n' is independently an integer from 0 to 3; and

15 if n' is 0 then R^{2a}, R^{2b}, R^{2c} or R^{2d} is absent.


2. The cyclic peptide of claim 1, wherein R^{1a}, R^{1b}, and R^{1c} are each independently selected from the group consisting of phenyl, naphthyl, and anthracenyl.

20 3. The cyclic peptide of claim 1, wherein the cyclic peptide is of Formula (IIa):




(IIa).

4. The cyclic peptide of any of claims 1-3, wherein at least one of R^{2a} , R^{2b} , R^{2c} , or R^{2d} is




, and the remaining R^{2a} , R^{2b} , R^{2c} , or R^{2d} are guanidine, or a protonated form thereof.

5. The cyclic peptide of any of claims 1-3, wherein at least two R^{2a} , R^{2b} , R^{2c} , or R^{2d} are



and the remaining R^{2a} , R^{2b} , R^{2c} , or R^{2d} are guanidine, or a protonated form thereof.

6. The cyclic peptide of any of claims 1-5, wherein the cyclic peptide is of Formula (IIb):




(IIb).


-

8. The cyclic peptide of any one of claims 1-7, wherein AA_{SC} is a side chain of an asparagine residue, aspartic acid residue, glutamic acid residue, homoglutamic acid residue, or homoglutamate residue.

- 10



11. The cyclic peptide of any one of claims 1-10, having the structure:



- , or a protonated form thereof.

14. The cyclic peptide of any one of claims 1-10, wherein the AA_{SC} is conjugated to a linker.

15. The cyclic peptide of claim 13 or 14, wherein in the conjugated form the AA_{SC} is a side chain of an asparagine residue, glutamine residue, or homoglutamine residue.

16. The cyclic peptide of claim 13 or 14, wherein in the conjugated form the AA_{SC} is a side chain of a glutamine residue.

17. The cyclic peptide of any one of claims 1-16, wherein a cargo moiety is conjugated to AA_{SC} by a linker.

18. The cyclic peptide of any one of claims 14-17, wherein the linker comprises a -(OCH₂CH₂)_{z'}- subunit, wherein z' is an integer from 1 to 23.

19. The cyclic peptide of any one of claims 14-17, wherein the linker comprises:

(i) a -(OCH₂CH₂)_{z'}- subunit, wherein z' is an integer from 1 to 23;


(ii) one or more amino acid residues, such as a residue of glycine, β-alanine, 4-aminobutyric acid, 5-aminopentanoic acid or 6-aminohexanoic acid, or combinations thereof; or

(iii) combinations of (i) and (ii).

20. The cyclic peptide of any one of claims 14-17, wherein the linker comprises:

a -(OCH₂CH₂)_z- subunit, wherein z is an integer from 2 to 20.


21. The cyclic peptide of any one of claims 14-19, wherein the linker has the structure:



wherein:

x' is an integer from 1-23; y is an integer from 1-5; z' is an integer from 1-23; * is the point of attachment to the AA_{SC}, and AA_{SC} is a side chain of an amino acid residue of the cyclic peptide; and M is a bonding group.

22. The cyclic peptide of any one of claims 14-19, wherein the linker has the structure:



23. The cyclic peptide of claims 21 or 22, wherein z' is 11.

5

24. The cyclic peptide of any one of claims 21-23, wherein x' is 1.

25. An endosomal escape vehicle (EEV) comprising:

10

- (a) a cyclic peptide of any one of claims 1-12, wherein AA_{SC} is conjugated to a linker;
- (b) a linker comprising a -(OCH₂CH₂)_z- subunit, wherein z' is an integer from 1 to 23; and
- (c) an exocyclic peptide comprising from 2 to 10 amino acid residues, wherein the exocyclic peptide comprises 1 or 2 amino acid residues comprising a side chain

15

26. The EEV of claim 25, of Formula (B-4):

following sequences: KK, KR, RR, HH, HK, HR, RH, KKK, KGK, KBK, KBR, KRK, KRR, RKK, RRR, KKH, KHK, HKK, HRR, HRH, HHR, HBH, HHH, HHHH, KHKK, KKHK, KKKH, KHKH, HKHK, KKKK, KKRK, KRKK, KRRK, RKKR, RRRR, KGKK, KKGK, HBHBH, HBKBH, RRRRR, KKKKK, KKKRK, RKKKK, KRKKK, KKRKK, KKKKR, KBKKBK, RKKKKK, KRKKKK, KKKRKK, KKKKRG, RKKKKB, KRKKKB, KKRKKB, KKKKRB, KKKRKV, RRRRRR, HHHHHH, RHRHRH, HRHRHR, KRKRKR, RKRKRK, RBRBRB, KBKKBK, PKKKRKV, PGKKRKV, PKGKRKV, PKKGRKV, PKKKGKV, PKKKRGV or PKKKRKG.

32. The EEV of any one of claims 25-29, wherein the exocyclic peptide comprises one of the following sequences: PKKKRKV, RR, RRR, RHR, RBR, RBRBR, RBHBR, or HBRBH, wherein B is beta-alanine.

33. The EEV of any one of claims 25-29, wherein the exocyclic peptide comprises one of the following sequences: KK, KR, RR, KKK, KGK, KBK, KBR, KRK, KRR, RKK, RRR, KKKK, KKRK, KRKK, KRRK, RKKR, RRRR, KGKK, KKGK, KKKKK, KKKRK, KBKKB, KKKRKV, PKKKRKV, PGKKRKV, PKGKRKV, PKKGRKV, PKKKGKV, PKKKRGV or PKKKRKG.

34. The EEV of any one of claims 25-29, wherein the exocyclic peptide comprises one of the following sequences: PKKKRKV, RR, RRR, RHR, RBR, RBRBR, RBHBR, or HBRBH, wherein B is beta-alanine.


35. The EEV of any one of claims 25-30, wherein the exocyclic peptide comprises: Ac-PKKKRKV.

36. A compound comprising an EEV of any one of claims 25-34 conjugated to a cargo moiety, wherein the -OH of the terminal carboxylic acid group of the EEV is replaced by the cargo moiety.

37. The compound of claim 36, wherein the cargo moiety is a small molecule, peptide,

oligonucleotide, protein, antibody or derivatives thereof.

38. The compound of claims 36 or 37 comprising the structure of Formula (C-4):



(C-4)

or a protonated form thereof.

39. An EEV of formula: Ac-P-K-K-K-R-K-V-miniPEG-K(*cyclo*(Ff-Nal-GrGrQ))-PEG12-OH.

40. An EEV selected from:

Ac-rr-miniPEG2-Dap[cyclo(FfΦ-Cit-r-Cit-rQ)]-PEG12-OH

Ac-frr-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH

Ac-rfr-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH

Ac-rbfr-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH

Ac-rrr-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH

Ac-rbr-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH
 Ac-rbrbr-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH
 Ac-hh-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH
 Ac-hbh-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH
 Ac-hbhbbh-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH
 Ac-rbhbbh-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH
 Ac-hbrbh-PEG2-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-PEG12-OH
 Ac-rr-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-frr-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-rfr-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-rbfbr-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-rrr-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-rbr-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-rbrbr-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-hh-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-hbh-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-hbhbbh-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-rbhbbh-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-hbrbh-Dap(cyclo(FfΦ-Cit-r-Cit-rQ))-b-OH
 Ac-KKKK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KGKK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KKGK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KKK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KGK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KBK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KBKBK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KR-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-KBR-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-PKKKRKV-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2
 Ac-PKKKRKV-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH2

Ac-PGKKRKV-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂
 Ac-PKGKKRKV-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂
 Ac-PKKGRKV-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂
 Ac-PKKKGKV-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂
 Ac-PKKKRGV-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂
 Ac-PKKKRKG-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂
 Ac-KKKRK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂
 Ac-KKRK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂ and
 Ac-KRK-miniPEG2-Lys(cyclo(Ff-Nal-GrGrQ))-miniPEG2-K(N3)-NH₂.

41. The compound of any one of claims 36 – 38 for use in therapy.